The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis

Multiple sclerosis (MS) is a highly disabling, progressive neurodegenerative disease with no curative treatment available. Although significant progress has been made in understanding how MS develops, there remain aspects of disease pathogenesis that are yet to be fully elucidated. In this regard, s...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 946698
Main Authors Duarte-Silva, Eduardo, Ulrich, Henning, Oliveira-Giacomelli, Ágatha, Hartung, Hans-Peter, Meuth, Sven G., Peixoto, Christina Alves
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 28.07.2022
Subjects
adenosine
adenosine receptors
adenosinergic signaling
experimental autoimmune encephalomyelitis (EAE)
Immunology
multiple sclerosis (MS)
therapies
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2022.946698

Cover

More Information
Summary:Multiple sclerosis (MS) is a highly disabling, progressive neurodegenerative disease with no curative treatment available. Although significant progress has been made in understanding how MS develops, there remain aspects of disease pathogenesis that are yet to be fully elucidated. In this regard, studies have shown that dysfunctional adenosinergic signaling plays a pivotal role, as patients with MS have altered levels adenosine (ADO), adenosine receptors and proteins involved in the generation and termination of ADO signaling, such as CD39 and adenosine deaminase (ADA). We have therefore performed a literature review regarding the involvement of the adenosinergic system in the development of MS and propose mechanisms by which the modulation of this system can support drug development and repurposing.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Noel G. Carlson, The University of Utah, United States
Reviewed by: Michael Joseph Olek, Touro University Nevada, United States; Victor Rivera, Baylor College of Medicine, United States; Régis Guieu, Aix Marseille Université, France
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology
Present address: Eduardo Duarte-Silva, Center for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, Department of Pharmacology, University of São Paulo, São Paulo, Brazil
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.946698